Pasritamig
J&J's prostate-specific T-cell engager, notable for very little cytokine release in early trials.
Phase 1: PSA50 in ~40% at the recommended dose with CRS rates far below other engagers; phase 3 (KLK2-P3-01) in mCRPC after ARPI ± taxane began 2025.
No public structure of pasritamig; representative IgG shown.
Compare all products across the US, EU, UK, Japan, China and Australia →
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Pasritamig" OR ABSTRACT:"Pasritamig" OR TITLE:"JNJ-78278343" OR ABSTRACT:"JNJ-78278343") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pasritamig, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductXaluritamig
Shares CD3, Cytokine release syndrome (CRS), T-cell engagers (bispecific), Prostate cancer.
- CompanyXencor
Shares CD3, T-cell engagers (bispecific).
- TrialTOWER
Shares CD3, T-cell engagers (bispecific).
- PersonMichael von Bergwelt
Shares Cytokine release syndrome (CRS), T-cell engagers (bispecific).
- ProductTalquetamab
Shares Johnson & Johnson, CD3, T-cell engagers (bispecific).
- ProductElranatamab
Shares CD3, Cytokine release syndrome (CRS), T-cell engagers (bispecific).
- ProductOdronextamab
Shares CD3, T-cell engagers (bispecific).
- TrialIMCgp100-202
Shares CD3, T-cell engagers (bispecific).